The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy

References

• Karbasforooshan H, Roohbakhsh A, Karimi G. SIRT1 and microRNAs: the role in breast, lung and prostate cancers. Exp Cell Res. 2018;367(1):1–6.
   PubMed Web of Science ®Google Scholar
• Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–458.
   PubMed Web of Science ®Google Scholar
• Herold C, Reck T, Fischler P, et al. Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver. 2002;22(1):23–28.
   PubMedGoogle Scholar
• Coppola N, de Stefano G, Panella M, et al. Lowered expression of microRNA-125a-5p in human hepatocellular carcinoma and up-regulation of its oncogenic targets sirtuin-7, matrix metalloproteinase-11, and c-Raf. Oncotarget. 2017;8(15):25289.
   PubMedGoogle Scholar
• Luo J, Chen P, Xie W, et al. MicroRNA-138 inhibits cell proliferation in hepatocellular carcinoma by targeting Sirt1. Oncol Rep. 2017;38(2):1067–1074.
   PubMed Web of Science ®Google Scholar
• Karbasforooshan H, Karimi G. The role of SIRT1 in diabetic cardiomyopathy. Biomed Pharmacother. 2017;90:386–392.
   PubMed Web of Science ®Google Scholar
• Karbasforooshan H, Karimi G. The role of SIRT1 in diabetic retinopathy. Biomed Pharmacother. 2018;97:190–194.
   PubMed Web of Science ®Google Scholar
• Pan M, Yuan H, Brent M, et al. SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity. J Biol Chem. 2012;287(4):2468–2476.
   PubMed Web of Science ®Google Scholar
• Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer. 2011;2(6):648–662.
   PubMedGoogle Scholar
• Chen J, Zhang B, Wong N, et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 2011;71(12):4138–4149.
   PubMed Web of Science ®Google Scholar
• Elhanati S, Ben-Hamo R, Kanfi Y, et al. Reciprocal regulation between SIRT6 and miR-122 controls liver metabolism and predicts hepatocarcinoma prognosis. Cell Rep. 2016;14(2):234–242.
   PubMed Web of Science ®Google Scholar
• Shukla GC, Singh J, Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 2011;3(3):83–92.
   PubMedGoogle Scholar
• Zhou J, Zhou W, Kong F, et al. microRNA-34a overexpression inhibits cell migration and invasion via regulating SIRT1 in hepatocellular carcinoma. Oncol Lett. 2017;14(6):6950–6954.
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhu Y, Han H, et al. MicroRNA-148a deficiency promotes hepatic lipid metabolism and hepatocarcinogenesis in mice. Cell Death Dis. 2017;8(7):e2916–e2916.
   PubMedGoogle Scholar
• Prives C, Manley JL. Why is p53 acetylated? Cell. 2001;107(7):815–818.
   PubMed Web of Science ®Google Scholar
• Qin H, Ruan ZH. The role of monoacylglycerol lipase (MAGL) in the cancer progress. Cell Biochem Biophys. 2014 Sept;70(1):33–36.
   PubMed Web of Science ®Google Scholar
• Cassim S, Raymond V-A, Dehbidi-Assadzadeh L, et al. Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment. Cell Cycle. 2018;17(7):903–916.
   PubMed Web of Science ®Google Scholar
• Truman J-P, García-Barros M, Obeid LM, et al. Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta. 2014;1841(8):1174–1188.
   PubMed Web of Science ®Google Scholar
• Shamir Cassim V-AR, Lacoste B, Lapierre P, et al. Metabolite profiling identifies a signature of tumorigenicity in hepatocellular carcinoma. Oncotarget. 2018;9(42):26868.
   PubMedGoogle Scholar
• Zhang H, Feng Z, Huang R, et al. MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol. 2014;45(5):2143–2152.
   PubMed Web of Science ®Google Scholar
• Huang W-C, Li X, Liu J, et al. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res. 2012;10(1):133–142.
   PubMed Web of Science ®Google Scholar
• Chen B, Li H, Zeng X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med. 2012;10(1):228.
   PubMedGoogle Scholar
• Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell. 2006 Sept 1;10(3):175–176.
   PubMed Web of Science ®Google Scholar
• Pant K, Yadav AK, Gupta P, et al. Butyrate induces ROS-mediated apoptosis by modulating miR-22/SIRT-1 pathway in hepatic cancer cells. Redox Biol. 2017 Aug 1;12:340–349.
   PubMed Web of Science ®Google Scholar
• Galadari S, Rahman A, Pallichankandy S, et al. Reactive oxygen species and cancer paradox: to promote or to suppress? Free Radic Biol Med. 2017;104:144–164.
   PubMed Web of Science ®Google Scholar
• Cassim S, Vučetić M, Ždralević M, et al. Warburg and beyond: the power of mitochondrial metabolism to collaborate or replace fermentative glycolysis in cancer. Cancers (Basel). 2020;12(5):1119.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Takeuchi H, Sonobe Y, et al. Sirtuin 1 attenuates oxidative stress via upregulation of superoxide dismutase 2 and catalase in astrocytes. J Neuroimmunol. 2014;269(1–2):38–43.
   PubMed Web of Science ®Google Scholar
• Yang L, Sui W, Li Y, et al. Substance P inhibits hyperosmotic stress-induced apoptosis in corneal epithelial cells through the mechanism of akt activation and reactive oxygen species scavenging via the neurokinin-1 receptor. PLoS One. 2016;11(2):e0149865–e0149865.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Bertrand FE, et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget. 2014;5(10):2881–2911.
   PubMedGoogle Scholar
• Luo L-J, Zhang L-P, Duan C-Y, et al. The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147. Cancer Cell Int. 2017 Feb 2;17(1):17.
   PubMedGoogle Scholar
• Zhou L, He J, Zhang Y. MicroRNA-22 expression in hepatocellular carcinoma and its correlation with ezrin protein. J Int Med Res. 2013;41(4):1009–1016.
   PubMed Web of Science ®Google Scholar
• Chen S, Pu J, Bai J, et al. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis. J Exp Clin Cancer Res. 2018;37(1):1–12.
   PubMedGoogle Scholar
• Chen M, Hu W, Xiong C-L, et al. miR-22 targets YWHAZ to inhibit metastasis of hepatocellular carcinoma and its down-regulation predicts a poor survival. Oncotarget. 2016;7(49):80751.
   PubMedGoogle Scholar
• Weidle UH, Scheuer W, Eggle D, et al. Cancer-related issues of CD147. Cancer Genomics Proteomics. 2010 May-June;7(3):157–169.
   PubMedGoogle Scholar
• Yang F, Gong J, Wang G, et al. Waltonitone inhibits proliferation of hepatoma cells and tumorigenesis via FXR-miR-22-CCNA2 signaling pathway. Oncotarget. 2016;7(46):75165–75175.
   PubMedGoogle Scholar
• Wang W, Zhao L-J, Tan Y-X, et al. MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 2012;33(5):1113–1120.
   PubMed Web of Science ®Google Scholar
• Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46.
   PubMed Web of Science ®Google Scholar
• Shteingauz A, Boyango I, Naroditsky I, et al. Heparanase enhances tumor growth and chemoresistance by promoting autophagy. Cancer Res. 2015;75(18):3946–3957.
   PubMed Web of Science ®Google Scholar
• Lin Z, Yang H, Kong Q, et al. USP22 antagonizes p53 transcriptional activation by deubiquitinating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development. Mol Cell. 2012;46(4):484–494.
   PubMed Web of Science ®Google Scholar
• Xiong H, Ni Z, He J, et al. LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells. Oncogene. 2017 June 22;36(25):3528–3540.
   PubMed Web of Science ®Google Scholar
• Jiang G, Wen L, Zheng H, et al. miR‐204‐5p targeting SIRT1 regulates hepatocellular carcinoma progression. Cell Biochem Funct. 2016;34(7):505–510.
   PubMed Web of Science ®Google Scholar
• Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–874.
   PubMed Web of Science ®Google Scholar
• Yoshimoto R, Mayeda A, Yoshida M, et al. MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta. 2016 Jan;1859(1):192–199.
   PubMed Web of Science ®Google Scholar
• Hou Z, Xu X, Zhou L, et al. The long non-coding RNA MALAT1 promotes the migration and invasion of hepatocellular carcinoma by sponging miR-204 and releasing SIRT1. Tumour Biol. 2017;39(7):1010428317718135.
   Google Scholar
• Lima RT, Busacca S, Almeida GM, et al. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer. 2011;47(2):163–174.
   PubMed Web of Science ®Google Scholar
• Guo L, Bai H, Zou D, et al. The role of microRNA-133b and its target gene FSCN1 in gastric cancer. J Exp Clin Cancer Res. 2014;33(1):99.
   PubMedGoogle Scholar
• Tian Z, Jiang H, Liu Y, et al. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1. Exp Cell Res. 2016 May 1;343(2):135–147.
   PubMed Web of Science ®Google Scholar
• Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancer. Cell Cycle. 2008;7(18):2787–2790.
   PubMed Web of Science ®Google Scholar
• Wu Y, Liu H, Weng H, et al. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol. 2015 Mar;46(3):1275–1285.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang L, Wang S, et al. MiR-29a suppresses cell proliferation by targeting SIRT1 in hepatocellular carcinoma. Cancer Biomark. 2018;22(1):151–159.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Fang JH, Yun JP, et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010 Mar;51(3):836–845.
   PubMed Web of Science ®Google Scholar
• Kogure T, Kondo Y, Kakazu E, et al. Involvement of mi RNA‐29a in epigenetic regulation of transforming growth factor‐β‐induced epithelial–mesenchymal transition in hepatocellular carcinoma. Hepatol Res. 2014;44(8):907–919.
   PubMed Web of Science ®Google Scholar
• Rastogi N, Mishra DP. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div. 2012 Dec 26;7(1):26.
   PubMedGoogle Scholar
• Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. 2014;33(20):2557–2567.
   PubMed Web of Science ®Google Scholar
• Wang JY, Jiang JB, Li Y, et al. MicroRNA-299-3p suppresses proliferation and invasion by targeting VEGFA in human colon carcinoma. Biomed Pharmacother. 2017 Sept;93:1047–1054.
   PubMed Web of Science ®Google Scholar
• Bringman-Rodenbarger LR, Guo AH, Lyssiotis CA, et al. Emerging roles for SIRT5 in metabolism and cancer. Antioxid Redox Signal. 2018;28(8):677–690.
   PubMed Web of Science ®Google Scholar
• Dang S, Zhou J, Wang Z, et al. MiR-299-3p functions as a tumor suppressor via targeting Sirtuin 5 in hepatocellular carcinoma. Biomed Pharmacother. 2018;106:966–975.
   PubMed Web of Science ®Google Scholar
• Marquardt JU, Fischer K, Baus K, et al. Sirtuin-6–dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. Hepatology. 2013;58(3):1054–1064.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (New York, NY). 2009;324(5930):1029–1033.
   Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008;13(6):472–482.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7(1):11–20.
   PubMed Web of Science ®Google Scholar
• Cassim S, Pouyssegur J. Tumor microenvironment: a metabolic player that shapes the immune response. Int J Mol Sci. 2020;21(1):157.
   Web of Science ®Google Scholar
• Lin CJ-F, Gong H-Y, Tseng H-C, et al. miR-122 targets an anti-apoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun. 2008;375(3):315–320.
   PubMed Web of Science ®Google Scholar
• Hromadnikova I, Kotlabova K, Ondrackova M, et al. Expression profile of C19MC microRNAs in placental tissue in pregnancy-related complications. DNA Cell Biol. 2015;34(6):437–457.
   PubMed Web of Science ®Google Scholar
• Liu X, Yang L, Tu J, et al. microRNA-526b servers as a prognostic factor and exhibits tumor suppressive property by targeting Sirtuin 7 in hepatocellular carcinoma. Oncotarget. 2017;8(50):87737–87749.
   PubMedGoogle Scholar
• Yoshida S, Kornek M, Ikenaga N, et al. Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 2013 Nov;58(5):1667–1680.
   PubMed Web of Science ®Google Scholar
• Huang X-H, Jian W-H, Wu Z-F, et al. Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation. Oncotarget. 2014;5(14):5570.
   PubMedGoogle Scholar
• Potenza N, Mosca N, Zappavigna S, et al. MicroRNA‐125a‐5p is a downstream effector of sorafenib in its antiproliferative activity toward human hepatocellular carcinoma cells. J Cell Physiol. 2017;232(7):1907–1913.
   PubMed Web of Science ®Google Scholar
• Kim JK, Noh JH, Jung KH, et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR‐125a‐5p and MiR‐125b. Hepatology. 2013;57(3):1055–1067.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wang W. miR-125b suppresses the proliferation of hepatocellular carcinoma cells by targeting Sirtuin7. Int J Clin Exp Med. 2015;8(10):18469–18475.
   PubMed Web of Science ®Google Scholar
• Goedeke L, Wagschal A, Fernández-Hernando C, et al. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta. 2016;1861(12):2047–2052.
   PubMed Web of Science ®Google Scholar
• Li L, Liu Y, Guo Y, et al. Regulatory MiR‐148a‐ACVR1/BMP circuit defines a cancer stem cell‐like aggressive subtype of hepatocellular carcinoma. Hepatology. 2015;61(2):574–584.
   PubMed Web of Science ®Google Scholar